Llerena A - Search Results

1

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.

Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR. Llerena A, et al. Pharmacogenomics J. 2012 Apr;12(2):176-83. doi: 10.1038/tpj.2010.85. Epub 2010 Dec 7. Pharmacogenomics J. 2012. PMID: 21135868

2

Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.

LLerena A, Berecz R, de la Rubia A, Fernández-Salguero P, Dorado P. LLerena A, et al. Ther Drug Monit. 2001 Dec;23(6):616-20. doi: 10.1097/00007691-200112000-00004. Ther Drug Monit. 2001. PMID: 11802093

3

CYP2C9 gene and susceptibility to major depressive disorder.

LLerena A, Berecz R, Dorado P, González AP, Peñas-LLedó EM, De La Rubia A. LLerena A, et al. Pharmacogenomics J. 2003;3(5):300-2. doi: 10.1038/sj.tpj.6500197. Pharmacogenomics J. 2003. PMID: 14583800

4

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

Dorado P, Berecz R, Peñas-Lledó EM, Cáceres MC, Llerena A. Dorado P, et al. Among authors: llerena a. Curr Drug Targets. 2006 Dec;7(12):1671-80. doi: 10.2174/138945006779025329. Curr Drug Targets. 2006. PMID: 17168842 Review.

5

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.

Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A. Llerena A, et al. Pharmacogenomics J. 2007 Dec;7(6):408-10. doi: 10.1038/sj.tpj.6500439. Epub 2007 Feb 27. Pharmacogenomics J. 2007. PMID: 17325735

6

CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards.

Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong ML, Licinio J, Lares-Asseff I, Llerena A. Dorado P, et al. Among authors: llerena a. Pharmacogenomics J. 2011 Apr;11(2):108-12. doi: 10.1038/tpj.2010.29. Epub 2010 May 11. Pharmacogenomics J. 2011. PMID: 20458343

7

CYP2D6 polymorphism in patients with eating disorders.

Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda F, Llerena A. Peñas-Lledó EM, et al. Among authors: llerena a. Pharmacogenomics J. 2012 Apr;12(2):173-5. doi: 10.1038/tpj.2010.78. Epub 2010 Sep 28. Pharmacogenomics J. 2012. PMID: 20877302

8

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.

Dorado P, López-Torres E, Peñas-Lledó EM, Martínez-Antón J, Llerena A. Dorado P, et al. Among authors: llerena a. Pharmacogenomics J. 2013 Aug;13(4):359-61. doi: 10.1038/tpj.2012.19. Epub 2012 May 29. Pharmacogenomics J. 2013. PMID: 22641027

9

Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6.

González-Vacarezza N, Abad-Santos F, Carcas-Sansuan A, Dorado P, Peñas-Lledó E, Estévez-Carrizo F, Llerena A. González-Vacarezza N, et al. Among authors: llerena a. Pharmacogenomics J. 2013 Oct;13(5):452-5. doi: 10.1038/tpj.2012.29. Epub 2012 Jun 26. Pharmacogenomics J. 2013. PMID: 22733239 Clinical Trial.

10

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.

Llerena A, Alvarez M, Dorado P, González I, Peñas-LLedó E, Pérez B, Cobaleda J, Calzadilla LR. Llerena A, et al. Pharmacogenomics J. 2014 Jun;14(3):229-34. doi: 10.1038/tpj.2013.28. Epub 2013 Aug 20. Pharmacogenomics J. 2014. PMID: 23959274

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters